Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
|Articles|May 23, 2016
Sanofi Loses Three Top Execs in Reshuffle
May 23, 2016.
Advertisement
Three of Sanofi's (Paris, France) top executives are leaving the company as its "2020 strategic roadmap" gets under way.
Pascale Witz, executive vice president of diabetes and cardiovascular, Carsten Hellmann, executive vice president of Merial, Sanofi’s animal health division, and Suresh Kumar, executive vice president of external affairs, have announced their intention to leave the company.
Hellmann has accepted a position as president and CEO of ALK (Horsholm, Denmark).
Advertisement
Related to this article
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
4
MFN Is an Offer Pharma Can’t Refuse
5